These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34750662)

  • 1. Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis.
    Xue JS; Liu H; Meng GX; Ding ZN; Yan LJ; Yao SY; Li HC; Dong ZR; Chen ZQ; Hong JG; Li T
    Cancer Immunol Immunother; 2022 Jul; 71(7):1633-1644. PubMed ID: 34750662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
    Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
    Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis.
    Li XS; Li JW; Li H; Jiang T
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32255189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of the prognostic value of soluble programmed death ligand-1 (sPD-L1) in cancers.
    Sun J; Hu S; Li X
    Biomarkers; 2023 Sep; 28(6):477-485. PubMed ID: 37017446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients.
    El-Gebaly F; Abou-Saif S; Elkadeem M; Helmy A; Abd-Elsalam S; Yousef M; Elkhouly RA; Amer IF; El-Demerdash T
    Curr Cancer Drug Targets; 2019; 19(11):896-905. PubMed ID: 31538897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
    Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
    Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
    Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis.
    Scirocchi F; Strigari L; Di Filippo A; Napoletano C; Pace A; Rahimi H; Botticelli A; Rughetti A; Nuti M; Zizzari IG
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma.
    Mocan T; Ilies M; Nenu I; Craciun R; Horhat A; Susa R; Minciuna I; Rusu I; Mocan LP; Seicean A; Iuga CA; Hajjar NA; Sparchez M; Leucuta DC; Sparchez Z
    Int Immunopharmacol; 2021 May; 94():107467. PubMed ID: 33611059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
    Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF
    Front Immunol; 2018; 9():2077. PubMed ID: 30254644
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis.
    Li X; Zheng Y; Yue F
    Target Oncol; 2021 Jan; 16(1):13-26. PubMed ID: 33222017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta-analysis.
    Ding Y; Sun C; Li J; Hu L; Li M; Liu J; Pu L; Xiong S
    Scand J Immunol; 2017 Nov; 86(5):361-367. PubMed ID: 28930374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis.
    Huang P; Hu W; Zhu Y; Wu Y; Lin H
    Front Oncol; 2020; 10():626932. PubMed ID: 33718120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis.
    Ding Y; Sun C; Hu L; Xiong S; Zhai Z
    Ann Hematol; 2023 Sep; 102(9):2425-2434. PubMed ID: 37382610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization.
    Ma XL; Qu XD; Yang WJ; Wang BL; Shen MN; Zhou Y; Zhang CY; Sun YF; Chen JW; Hu B; Gong ZJ; Zhang X; Pan BS; Zhou J; Fan J; Yang XR; Guo W
    Clin Chim Acta; 2020 Dec; 511():67-74. PubMed ID: 32979338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis.
    Wei W; Xu B; Wang Y; Wu C; Jiang J; Wu C
    Medicine (Baltimore); 2018 Jan; 97(3):e9617. PubMed ID: 29504990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
    Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive role of soluble programmed death ligand 1 in digestive system cancers.
    Ruan J; Zhao Z; Qian Y; Xu R; Liao G; Kong FS
    Front Oncol; 2023; 13():1170220. PubMed ID: 37519785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
    Carosio R; Fontana V; Mastracci L; Ferro P; Grillo F; Banelli B; Canessa PA; Dessanti P; Vigani A; Morabito A; Pfeffer U; Poggi A; Roncella S; Pistillo MP
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):459-468. PubMed ID: 33216211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
    Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
    Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.